Pharmagen, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mackie A. Barch
- Full Time Employees
- 24
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Address
- 9337 Fraser Avenue Silver Spring MD United States of America 20910
- IPO Date
- Mar 8, 2012
- CIK
- 0001470915
- Website
- pharmageninc.com
- Similar Companies
- Business
- Pharmagen, Inc. operates as a key supplier within the United States healthcare sector, providing specialized pharmaceuticals to a network of hospitals, acute care facilities, ambulatory surgery centers, and various other medical practitioners. The company's core activities involve procuring and distributing a diverse array of crucial medications, encompassing specialty drugs, blood plasma-derived therapies, particular product lines, vital vaccines, anti-infective agents, and other difficult-to-source pharmaceuticals. These offerings include plasma derivatives specifically used to address severe medical conditions such as cancer, hemophilia, rheumatoid arthritis, multiple sclerosis, various blood disorders, hepatitis, and HIV. Additionally, it supplies specialized products targeting ailments within the respiratory, oncology, cardiovascular, and hormonal system categories. Beyond distribution, Pharmagen also engages in the production and dissemination of health supplements, notably featuring Clotamin, an exclusive over-the-counter multivitamin dietary supplement developed for individuals undergoing Warfarin therapy. The company's portfolio extends to the sale of conventional pharmaceuticals, including antibiotics, vaccines, and a range of oral and injectable medications, to its established distribution clientele. Furthermore, Pharmagen holds expertise in the formulation and compounding of drugs, which allows it to provide customized pharmaceutical solutions and innovative IT solutions to meet market demands. Established originally as Sunpeaks Ventures, Inc., the organization rebranded to Pharmagen, Inc. in January 2013 to better reflect its pharmaceutical focus. The company is strategically situated in Silver Spring, Maryland.
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring
PharmaDrug Announces Debt Restructuring
PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc
PharmaDrug Inc.: Correction to News Release Dated July 30, 2025
PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc.
PharmaDrug Announces Resignation of Rob Steen as CEO and From Board of Directors
PharmaDrug Announces Strategic Review Process Intended to Maximize Shareholder Value
PharmaDrug Announces Issuance of Debenture Units
PharmaDrug Announces Proposed Issuance of Debenture Units
PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins